Lysogene (LYS.PA) Stock Price & Overview
EPA:LYS • FR0013233475
Current stock price
The current stock price of LYS.PA is 0.2795 EUR. Today LYS.PA is down by -0.71%. In the past month the price decreased by -48.05%. In the past year, price decreased by -85.38%.
LYS.PA Key Statistics
- Market Cap
- 4.969M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.81
- Dividend Yield
- N/A
LYS.PA Stock Performance
LYS.PA Stock Chart
LYS.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LYS.PA. When comparing the yearly performance of all stocks, LYS.PA is a bad performer in the overall market: 99.11% of all stocks are doing better.
LYS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LYS.PA. Both the profitability and financial health of LYS.PA have multiple concerns.
LYS.PA Earnings
LYS.PA Forecast & Estimates
7 analysts have analysed LYS.PA and the average price target is 11.22 EUR. This implies a price increase of 3914.31% is expected in the next year compared to the current price of 0.2795.
For the next year, analysts expect an EPS growth of -37.04% and a revenue growth -50% for LYS.PA
LYS.PA Groups
Sector & Classification
LYS.PA Financial Highlights
Over the last trailing twelve months LYS.PA reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS decreased by -150.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LYS.PA Ownership
LYS.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.73 | 40.051B | ||
| 1AE | ARGENX SE | 26.69 | 39.989B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.659B | ||
| 2X1 | ABIVAX SA | N/A | 8.034B | ||
| ABVX | ABIVAX SA | N/A | 8.018B | ||
| GXE | GALAPAGOS NV | N/A | 1.691B | ||
| GLPG | GALAPAGOS NV | N/A | 1.687B | ||
| NANO | NANOBIOTIX | N/A | 1.326B | ||
| 6IV | INVENTIVA SA | N/A | 981.136M | ||
| IVA | INVENTIVA SA | N/A | 980.098M | ||
| PHIL | PHILOGEN SPA | 17.77 | 649.128M | ||
| GNFT | GENFIT | 846.08 | 431.525M | ||
| FYB | FORMYCON AG | N/A | 329.015M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About LYS.PA
Company Profile
Lysogene SA engages in the research and clinical development of gene therapy for neurodegenerative disorders. The company is headquartered in Neuilly-Sur-Seine, Ile-De-France and currently employs 23 full-time employees. The company went IPO on 2017-02-08. The firm is focused on the gene therapy biotechnology. The firm develops treatments targeting severe genetic pathologies with central nervous system involvement and high unmet medical needs. The company is specialized in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.
Company Info
IPO: 2017-02-08
Lysogene
18-20 rue Jacques Dulud
Neuilly-sur-Seine ILE-DE-FRANCE FR
Employees: 23
Phone: 33141430390.0
Lysogene / LYS.PA FAQ
What does Lysogene do?
Lysogene SA engages in the research and clinical development of gene therapy for neurodegenerative disorders. The company is headquartered in Neuilly-Sur-Seine, Ile-De-France and currently employs 23 full-time employees. The company went IPO on 2017-02-08. The firm is focused on the gene therapy biotechnology. The firm develops treatments targeting severe genetic pathologies with central nervous system involvement and high unmet medical needs. The company is specialized in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.
What is the stock price of Lysogene today?
The current stock price of LYS.PA is 0.2795 EUR. The price decreased by -0.71% in the last trading session.
Does Lysogene pay dividends?
LYS.PA does not pay a dividend.
How is the ChartMill rating for Lysogene?
LYS.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for Lysogene?
Lysogene (LYS.PA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for LYS stock?
Lysogene (LYS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).